With a portfolio of 14 potential blockbuster treatments that it expects to launch over the next five years, GSK is sticking ...

Investors will focus on profits from asthma drug Dupixent and sales of Eylea HD when biotech giant Regeneron Pharmaceuticals, ...

Dupixent is indicated for the approximately 300,000 adults in the U.S. with inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype Following recent ...

Approval based on Phase 3 trials demonstrating Dupixent significantly reduced itch and hives compared to placebo In the U.S., there are more than 300,000 adults and adolescents aged 12 years and ...

DUPIXENT may also help reduce the amount of oral corticosteroids you need while preventing severe asthma attacks and improving your breathing. DUPIXENT is not used to treat sudden breathing problems.

Dupixent included in list of overseas approved drugs that meet urgent clinical need in China. Regeneron Pharmaceuticals, Inc. and Sanofi today announced that the National Medical Products ...

About Dupixent Dupixent, which was invented using Regeneron’s proprietary VelocImmune® technology, is a fully human monoclonal antibody that inhibits the signaling of the interleukin-4 (IL-4 ...

The company reaffirmed its target to achieve sales of Dupixent, jointly developed with Regeneron (REGN.O), of 10 billion euros this year, up more than 20% from 8.29 billion euros in 2022.

Dupixent, an interleukin-4 receptor alpha antagonist, is the first treatment indicated for prurigo nodularis. Credit: Getty Images. The Food and Drug Administration (FDA) has approved Dupixent ...

Dupixent is already approved in the EU for certain adults and adolescents aged 12 years and older with EoE. The positive CHMP opinion is supported by a two-part (Part A and B) EoE KIDS phase 3 ...

PARIS, Jan 30 (Reuters) - Healthcare companies Sanofi (SASY.PA), opens new tab and Regeneron (REGN.O), opens new tab said on Monday that their Dupixent product had won approval from the European ...

Dupixent is now approved in the U.S. to treat eight distinct diseases with underlying type 2 inflammation, including diseases of the skin, gut, and respiratory system that affect a broad range of ...